中华传染病杂志
中華傳染病雜誌
중화전염병잡지
CHINESE JOURNAL OF INFECTIOUS DISEASES
2009年
4期
193-197
,共5页
张玥%方风琴%章莉%倪语星%王祥慧%季育华
張玥%方風琴%章莉%倪語星%王祥慧%季育華
장모%방풍금%장리%예어성%왕상혜%계육화
巨细胞病毒%基因,病毒%点突变%抗药性,病毒%转染%重组,遗传
巨細胞病毒%基因,病毒%點突變%抗藥性,病毒%轉染%重組,遺傳
거세포병독%기인,병독%점돌변%항약성,병독%전염%중조,유전
Cytomegalovirus%Genes,viral%Point mutation%Drug resistance,viral%Transfection%Recombination,genetic
目的 构建含UL97基因耐药相关突变的重组人巨细胞病毒(rHCMV),并通过耐药表型和基因型加以鉴定.方法 采用重叠延伸剪接PCR在UL97基因中引入Pine I位点和耐药相关位点做定点突变,将所获突变基因片段按比例与人巨细胞病毒(HCMV)AD169标准株DNA混合,经脂质体介导共转染成纤维细胞MRC-5.利用间接免疫荧光检测HCMV PP65抗原,证实MRC-5已被rHCMV感染,观察同源重组病毒形成的细胞病变达100%后收获该重组病毒.用不同浓度更昔洛韦进行噬斑筛选纯化目的 病毒,并通过噬斑减少试验和耐药基因(UL97和UL54)序列分析对重组病毒进行鉴定.结果 成功构建目的 突变UL97基因片段,同病毒基因组DNA共转染7 d后可见明显细胞病变,PP65抗原检测证实为rHCMV感染灶.经过克隆筛选得到的重组病毒株UL97基因型分析结果与预期一致,UL54基因测序未发现突变.阳性克隆重组病毒对更昔洛韦敏感性显示半数抑制浓度(IC50)为15 μmol/L,是标准株的12倍,具耐药表型.结论 成功将HCMV基因组DNA与耐药突变目的 基因片段共转染MRC-5细胞,通过更昔洛韦筛选和噬斑纯化获得目的 重组病毒株.该方法的建立为在用药过程中不断出现的新的HCMV耐药突变株的鉴定分析提供了有效的技术平台.
目的 構建含UL97基因耐藥相關突變的重組人巨細胞病毒(rHCMV),併通過耐藥錶型和基因型加以鑒定.方法 採用重疊延伸剪接PCR在UL97基因中引入Pine I位點和耐藥相關位點做定點突變,將所穫突變基因片段按比例與人巨細胞病毒(HCMV)AD169標準株DNA混閤,經脂質體介導共轉染成纖維細胞MRC-5.利用間接免疫熒光檢測HCMV PP65抗原,證實MRC-5已被rHCMV感染,觀察同源重組病毒形成的細胞病變達100%後收穫該重組病毒.用不同濃度更昔洛韋進行噬斑篩選純化目的 病毒,併通過噬斑減少試驗和耐藥基因(UL97和UL54)序列分析對重組病毒進行鑒定.結果 成功構建目的 突變UL97基因片段,同病毒基因組DNA共轉染7 d後可見明顯細胞病變,PP65抗原檢測證實為rHCMV感染竈.經過剋隆篩選得到的重組病毒株UL97基因型分析結果與預期一緻,UL54基因測序未髮現突變.暘性剋隆重組病毒對更昔洛韋敏感性顯示半數抑製濃度(IC50)為15 μmol/L,是標準株的12倍,具耐藥錶型.結論 成功將HCMV基因組DNA與耐藥突變目的 基因片段共轉染MRC-5細胞,通過更昔洛韋篩選和噬斑純化穫得目的 重組病毒株.該方法的建立為在用藥過程中不斷齣現的新的HCMV耐藥突變株的鑒定分析提供瞭有效的技術平檯.
목적 구건함UL97기인내약상관돌변적중조인거세포병독(rHCMV),병통과내약표형화기인형가이감정.방법 채용중첩연신전접PCR재UL97기인중인입Pine I위점화내약상관위점주정점돌변,장소획돌변기인편단안비례여인거세포병독(HCMV)AD169표준주DNA혼합,경지질체개도공전염성섬유세포MRC-5.이용간접면역형광검측HCMV PP65항원,증실MRC-5이피rHCMV감염,관찰동원중조병독형성적세포병변체100%후수획해중조병독.용불동농도경석락위진행서반사선순화목적 병독,병통과서반감소시험화내약기인(UL97화UL54)서렬분석대중조병독진행감정.결과 성공구건목적 돌변UL97기인편단,동병독기인조DNA공전염7 d후가견명현세포병변,PP65항원검측증실위rHCMV감염조.경과극륭사선득도적중조병독주UL97기인형분석결과여예기일치,UL54기인측서미발현돌변.양성극륭중조병독대경석락위민감성현시반수억제농도(IC50)위15 μmol/L,시표준주적12배,구내약표형.결론 성공장HCMV기인조DNA여내약돌변목적 기인편단공전염MRC-5세포,통과경석락위사선화서반순화획득목적 중조병독주.해방법적건립위재용약과정중불단출현적신적HCMV내약돌변주적감정분석제공료유효적기술평태.
Objective To construct drug-resistant variant recombinant human cytomegalovirus (rHCMV)and identify drug susceptibility by phenotypic and genotypic assays.Methods The UL97 fragments containing Pine I recongnition site and resistant mutation were introduced by site-directed mutagenesis using gene splicing by overlap extension polymerase chain reaction(PCR),and blended with human cytomegalo-virus(HCMV)standard strain ADl 69 genomic DNA proportionally,then the DNA mixture were transfected into MRC-5 fibroblasts by the vector of liposomes.HCMV-PP65 antigen was detected by indirect-immunofluorescent assay to verify rHCMV infection of MRC-5 fibroblasts.When the eytopathic effect(CPE)of homologous recombinant virus reached 100%,the virus was harvested.The purified target virus was screened by plague with different concentrations of ganciclovir(GCV)and the recombinant virus was identified by plague reduction test and DNA sequencing of drug-resistant genes(UL97 and UL54).Results The UL97 fragments containing intended mutations for transfection were constructed successfully.After cotransfected with AD169DNA mixture for 7 days,rHCMV formed cytopathology was obviously visible,which was verified as rHCMV infected focus by HCMV-PP65 antigen test.The UL97 genotypic analysis of recombinant virus obtained by cloning was as expected.No mutation was found by UL54 gene sequencing.The GCV susceptibility of rHCMV positive clone was 15 μmol/L (50% inhibiting concentration),which was 12-fold of standard AD169 strain and was drug-resistant phenotype.Conclusions The rHCMV containing intended mutations is constructed successfully by cotransfeetion into MRC-5 cells and the recombinant virus strain is obtained by GCV screening and plaque purifying.The establishment of this method provides technique platform for identifications of new drug-resistant mutations of HCMV during anti-viral therapy.